B-cell lymphoma
Drug research and approvals for B-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 784 studies of B-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 74 drug trials for it since 2013, FDA has 26 approved and 23 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 784
- Trials authorized in Canada: 74
- FDA orphan approvals: 26
- EU medicines: 7
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational StudyNCT07895927 · Not reported · University Hospital, Strasbourg, France · starts Feb 11, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 10, 2026
Approved 10
- Polatuzumab vedotinDiffuse large B-cell lymphoma · B-cell antigen receptor complex-associated protein beta chain binding agent
- TafasitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
- GlofitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- Axicabtagene ciloleucelDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
- Loncastuximab tesirineDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
- TisagenlecleucelDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
- SelinexorDiffuse large B-cell lymphoma · Exportin-1 inhibitor
- EpcoritamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- VinblastineDiffuse large B-cell lymphoma · Tubulin inhibitor
- UmbralisibMarginal zone B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
Phase 3 12 of 60
- RituximabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- CyclophosphamideDiffuse large B-cell lymphoma · DNA inhibitor
- PrednisoneDiffuse large B-cell lymphoma · Glucocorticoid receptor agonist
- DoxorubicinDiffuse large B-cell lymphoma · DNA topoisomerase II alpha inhibitor
- VincristineDiffuse large B-cell lymphoma · Tubulin inhibitor
- LenalidomideDiffuse large B-cell lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- GemcitabineDiffuse large B-cell lymphoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
- CytarabineDiffuse large B-cell lymphoma · DNA inhibitor
- OxaliplatinDiffuse large B-cell lymphoma · DNA inhibitor
- ObinutuzumabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- ZanubrutinibDiffuse large B-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
- IfosfamideDiffuse large B-cell lymphoma · DNA inhibitor
Phase 2 12 of 89
- VenetoclaxDiffuse large B-cell lymphoma · Apoptosis regulator Bcl-2 inhibitor
- PembrolizumabDiffuse large B-cell lymphoma · Programmed cell death protein 1 inhibitor
- NivolumabDiffuse large B-cell lymphoma · Programmed cell death protein 1 inhibitor
- AtezolizumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
- DurvalumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
- BlinatumomabDiffuse large B-cell lymphoma · T cell surface glycoprotein CD3 cross-linking agent
- BusulfanDiffuse large B-cell lymphoma · DNA inhibitor
- MetforminDiffuse large B-cell lymphoma · Mitochondrial complex I (NADH dehydrogenase) inhibitor
- PanobinostatDiffuse large B-cell lymphoma · Histone deacetylase inhibitor
- TacrolimusDiffuse large B-cell lymphoma · FK506-binding protein 1A inhibitor
- BelinostatDiffuse large B-cell lymphoma · Histone deacetylase inhibitor
- CopanlisibDiffuse large B-cell lymphoma · PI3-kinase p110-alpha subunit inhibitor
Phase 1 or earlier 12 of 61
- CarfilzomibDiffuse large B-cell lymphoma · 26S proteasome inhibitor
- AvadomideDiffuse large B-cell lymphoma
- IMM-0306
- Valproic acidDiffuse large B-cell lymphoma · Succinate semialdehyde dehydrogenase inhibitor
- ZandelisibDiffuse large B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
- OnatasertibDiffuse large B-cell lymphoma · Serine/threonine-protein kinase mTOR inhibitor
- AlisertibBurkitt lymphoma · Serine/threonine-protein kinase Aurora-A inhibitor
- TanespimycinBurkitt lymphoma · Heat shock protein HSP90 inhibitor
- VistusertibDiffuse large B-cell lymphoma · Serine/threonine-protein kinase mTOR inhibitor
- TazemetostatDiffuse large B-cell lymphoma · Histone-lysine N-methyltransferase EZH2 inhibitor
- ParsaclisibDiffuse large B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
- IrinotecanBurkitt lymphoma · DNA topoisomerase I inhibitor
How its trials ended
1,592 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 414 whose ending is known, 38% met their primary endpoint, 3% missed it and 59% stopped early.
- Ongoing60638%
- Completed, result not reported36923%
- Status unknown20313%
- Met its primary endpoint15610%
- Stopped: other or unclear956%
- Stopped: sponsor or business decision574%
- Stopped: enrollment or feasibility483%
- Stopped: lack of efficacy242%
- Stopped: funding161%
- Missed its primary endpoint141%
- Stopped: safety4<1%
| Oct 30, 2026 | A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140) | Merck & Co. (MSD) | Pending |
| Oct 16, 2026 | A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979) | Regeneron | Pending |
| Jul 23, 2026 | A phase III study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) in…Surovatamig | AstraZeneca Pharmaceuticals | Pending |
| Apr 10, 2026 | A phase 3, randomized, open-label, multicenter study evaluating the efficacy of KITE-753 versus axicabtagene ciloleucel in participants with relapsed and/or…KITE-753 | Kitepharma Inc | Ongoing |
| Mar 11, 2026 | A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous ANTI-CD19/CD20 car T-cell therapies, in…KITE-753 | Kitepharma Inc | Ongoing |
| Feb 20, 2026 | A phase 3 randomized controlled trial of rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 car T-cell product candidate, versus investigator’s…Rondecabtagene autoleucel | Lyell Immunopharma | Ongoing |
| Jun 20, 2025 | An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /… | Treeline Biosciences | Ongoing |
| Mar 7, 2025 | A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response…Cemacabtagene ansegedleucel | Allogene Therapeutics | Ongoing |
| Dec 13, 2024 | A randomized, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with r-chp versus r-chop in participants with previously…Zilovertamab vedotin (MK-2140) / Rituximab / Cyclophosphamide / Doxorubicin /… | Merck & Co. (MSD) | Ongoing |
| Dec 13, 2024 | A phase II, open-label, multicenter study to evaluate the optimization of the cytokine release syndrome profile for glofitamab in combination with gemcitabine…Columvi / Gazyva | Roche | Ongoing |
| Feb 5, 2026 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Apr 19, 2023 | PolivyIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have… | Genentech, Inc. | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Apr 1, 2022 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Apr 1, 2022 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Apr 1, 2022 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Dec 2, 2021 | RituxanTreatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell… | Genentech, Inc. | Approved |
| Apr 23, 2021 | ZynlontaTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | ADC Therapeutics SA | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jul 31, 2020 | MonjuviMONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell… | Incyte Corporation | Approved |
| Jun 22, 2020 | XpovioXPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise… | Karyopharm Therapeutics, Inc. | Approved |
| Sep 22, 2023 | TepkinlyEpcoritamab | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 7, 2023 | ColumviGlofitamab | Roche Registration GmbH | EMA ↗ |
| Dec 20, 2022 | ZynlontaLoncastuximab tesirine | Swedish Orphan Biovitrum AB | EMA ↗ |
| Apr 4, 2022 | BreyanziLisocabtagene maraleucel | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Aug 26, 2021 | MinjuviTafasitamab · orphan | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Jan 16, 2020 | PolivyPolatuzumab vedotin · orphan | Roche Registration GmbH | EMA ↗ |
| Aug 23, 2018 | YescartaAxicabtagene ciloleucel · orphan | Kite Pharma EU B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA